-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Reiterates Outperform on ArriVent BioPharma, Raises Price Target to $50

Benzinga·03/06/2026 17:19:40
Listen to the news
Oppenheimer analyst Jeff Jones reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and raises the price target from $44 to $50.